/SAVA

SAVA Stock - Cassava Sciences, Inc.

Q: What is the analyst price target for SAVA?

Analyst price target information is not currently available for SAVA.

Q: What is SAVA's market cap?

Market capitalization information is not currently available for SAVA.

Healthcare|Biotechnology|NASDAQ

$2.17-23.68%

$0.68 (-23.68%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $2.39

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for SAVA

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-1.09

52W High$4.98

52W Low$1.15

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	$-89,423,000	$-68,032,000	N/A	$-3,053,000
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-141,446,000	$-105,957,000	$-80,020,000	$-32,868,000	$-6,446,000
Net Income	$-24,342,000	$-97,217,000	$-76,246,000	$-32,385,000	$-6,334,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-0.53	$-2.32	$-1.80	$-0.81	$-0.22

Company Overview

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

25%

Hold / Neutral

75%

Sell / Underperform

Analyst Consensus🔴 Bearish

1 Bullish3 Neutral/Bearish

Price Targets

$80

Average Target

↑ 3578.2% Upside

Now

$44

Low

$80

Average

$116

High

Based on 2 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
November 26th 2024	H.C. Wainwright	Downgrade	Neutral	-
October 8th 2024	H.C. Wainwright	Upgrade	Buy	$116
July 1st 2024	H.C. Wainwright	Downgrade	Neutral	-
November 16th 2022	B. Riley Securities	Downgrade	Neutral	$44

Earnings History & Surprises

SAVA

Beat Rate

38%

Last 16 quarters

Avg Surprise

-20.7%

EPS vs Estimate

Beats / Misses

6/10

Last 12 quarters

Latest EPS

$-0.22

Q4 2025

EPS Surprise History

Q1 24

-25.0%

$-0.50vs$-0.40

Q2 24

-176.5%

$-1.41vs$-0.51

Q3 24

-190.9%

$-1.28vs$-0.44

Q4 24

+57.7%

$-0.58vs$-1.37

Q1 25

+16.2%

$-0.57vs$-0.68

Q2 25

No data

Q3 25

No data

Q4 25

+18.5%

$-0.22vs$-0.27

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 6, 2026	—	—	—	—
Q1 2026	Mar 2, 2026	—	—	—	—
Q4 2025	Nov 12, 2025	$-0.27	$-0.22	+18.5%	✓ BEAT
Q3 2025	Aug 14, 2025	—	$-0.18	—	—
Q2 2025	May 8, 2025	—	$-0.48	—	—
Q1 2025	Mar 3, 2025	$-0.68	$-0.57	+16.2%	✓ BEAT
Q4 2024	Nov 7, 2024	$-1.37	$-0.58	+57.7%	✓ BEAT
Q3 2024	Aug 8, 2024	$-0.44	$-1.28	-190.9%	✗ MISS
Q2 2024	May 10, 2024	$-0.51	$-1.41	-176.5%	✗ MISS
Q1 2024	Feb 28, 2024	$-0.40	$-0.50	-25.0%	✗ MISS
Q4 2023	Nov 7, 2023	$-0.90	$-0.61	+32.2%	✓ BEAT
Q3 2023	Aug 3, 2023	$-0.58	$-0.63	-8.6%	✗ MISS
Q2 2023	May 1, 2023	$-0.56	$-0.58	-3.6%	✗ MISS
Q1 2023	Feb 28, 2023	$-0.58	$-0.47	+19.0%	✓ BEAT
Q4 2022	Nov 7, 2022	$-0.47	$-0.51	-8.5%	✗ MISS
Q3 2022	Aug 3, 2022	$-0.42	$-0.48	-14.3%	✗ MISS
Q2 2022	May 5, 2022	$-0.43	$-0.44	-2.3%	✗ MISS
Q1 2022	Feb 28, 2022	$-0.41	$-0.35	+14.6%	✓ BEAT
Q4 2021	Nov 10, 2021	$-0.17	$-0.24	-41.2%	✗ MISS
Q3 2021	Aug 3, 2021	$-0.11	$-0.13	-18.2%	✗ MISS

Frequently Asked Questions about SAVA

What is SAVA's current stock price?

Cassava Sciences, Inc. (SAVA) is currently trading at $2.17 per share. The stock has moved -23.68% today.

What is the analyst price target for SAVA?

No analyst price targets are currently available for this stock.

What sector is Cassava Sciences, Inc. in?

Cassava Sciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is SAVA's market cap?

Cassava Sciences, Inc. has a market capitalization of $0.11 billion, making it a small-cap company.

Does SAVA pay dividends?

No, Cassava Sciences, Inc. does not currently pay a dividend to shareholders.